Estimation of VLDL, IDL, LDL, HDL₂, apoA-I, and apoB from the Friedewald inputs—apoB and IDL, but not LDL, are associated with mortality in type 1 diabetes

References

• Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation 2004; 109: 2–7
   PubMed Web of Science ®Google Scholar
• Mudd JO, Borlaug BA, Johnston PV, Kral BG, Rouf R, Blumenthal RS, et al. Beyond low-density lipoprotein cholesterol. J Am Coll Cardiol 2007; 50: 1735–41
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502
   PubMed Web of Science ®Google Scholar
• Warnick GR, Myers GL, Cooper GR, Rifai N. Impact of the third cholesterol report from the adult treatment panel of the national cholesterol education program on the clinical laboratory. Clin Chem 2002; 48: 11–17
   PubMed Web of Science ®Google Scholar
• Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026–33
   PubMed Web of Science ®Google Scholar
• Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005; 112: 3375–83
   PubMed Web of Science ®Google Scholar
• St-Pierre A, Cantin B, Dagenais GR, Mauriege P, Bernard PM, Despres JP, et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men. 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005; 25: 553–9
   PubMed Web of Science ®Google Scholar
• McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008; 372: 224–33
   PubMed Web of Science ®Google Scholar
• Ginsberg HN. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002; 106: 2137–42
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Dunn M, Liu CR, Liu CH, Selzer RH, et al. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation 1997; 95: 2022–6
   PubMed Web of Science ®Google Scholar
• Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993; 88: 2762–70
   Google Scholar
• Majeed F, Miller M. Low high-density lipoprotein cholesterol: an important consideration in coronary heart disease risk assessment. Curr Opin Endocrinol Diabetes Obes 2008; 2: 175–81
   Google Scholar
• Bruckert E, Hansel B. HDL-C is a powerful lipid predictor of cardiovascular diseases. Int J Clin Pract 2007; 11: 1905–13
   Google Scholar
• Morgan J, Carey C, Lincoff A, Capuzzi D. High-density lipoprotein subfractions and risk of coronary artery disease. Curr Atheroscler Rep 2004; 6: 359–65
   PubMedGoogle Scholar
• Savolainen MJ, Rantala M, Kervinen K, Järvi L, Suvanto K, Rantala T, et al. Magnitude of dietary effects on plasma cholesterol concentration: role of sex and apolipoprotein E phenotype. Atherosclerosis 1991; 86: 145–52
   PubMed Web of Science ®Google Scholar
• Hannuksela M, Marcel YL, Kesäniemi YA, Savolainen MJ. Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol. J Lipid Res 1992; 33: 737–44
   PubMed Web of Science ®Google Scholar
• Savolainen MJ, Korhonen T, Aalto-Setälä K, Kontula K, Kesäniemi YA. Screening for a prevalent LDL receptor mutation in patients with severe hypercholestrolaemia. Hum Genet 1991; 87: 125–8
   PubMed Web of Science ®Google Scholar
• Hörkkö S, Huttunen K, Korhonen T, Kesäniemi YA. Decreased clearance of low-density lipoprotein in patients with chronic renal failure. Kidney Int 1994; 45: 561–70
   PubMed Web of Science ®Google Scholar
• Ala-Korpela M, Korhonen A, Keisala J, Hörkkö S, Korpi P, Ingman LP, et al. 1H NMR-based absolute quantitation of human lipoproteins and their lipid contents directly from plasma. J Lipid Res 1994; 35: 2292–304
   PubMed Web of Science ®Google Scholar
• Mäkinen VP, Forsblom C, Thorn L, Wadén J, Gordin D, Heikkilä O, et al. FinnDiane Study Group. Metabolic phenotypes, vascular complications and premature deaths in a population of 4,197 patients with type 1 diabetes. Diabetes 2008; 57: 2480–7
   PubMed Web of Science ®Google Scholar
• Siggins S, Jauhiainen M, Olkkonen VM, Tenhunen J, Ehnholm C. PLTP secreted by HepG2 cells resembles the high-activity PLTP form in human plasma. J Lipid Res 2003; 44: 1698–704
   Google Scholar
• Baxt WG. Application of artificial neural networks to clinical medicine. Lancet 1995; 346: 1135–8
   PubMed Web of Science ®Google Scholar
• Väänänen T, Koskela H, Hiltunen Y, Ala-Korpela M. Application of quantitative artificial neural network analysis to 2D NMR spectra of hydrocarbon mixtures. J Chem Inf Comput Sci 2002; 42: 1343–6
   PubMedGoogle Scholar
• Bishop CM. Neural networks for pattern recognition. Oxford University Press, New York 1995
   Google Scholar
• Tolonen N, Forsblom C, Thorn L, Wadén J, Rosengård-Bärlund M, Saraheimo M, et al. Relationship between lipid profiles and kidney function in patients with type 1 diabetes. Diabetologia 2008; 51: 12–20
   Google Scholar
• Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307–10
   PubMed Web of Science ®Google Scholar
• Cox DR. Regression models and life tables. J Royal Stat Soc 1972; 34: 187–220
   Google Scholar
• Gazi I, Tsimihodimos V, Filippatos TD, Saougos VG, Bairaktari ET, Tselepis AD, et al. LDL cholesterol estimation in patients with the metabolic syndrome. Lipids Health Dis 2006; 5: 8
   PubMed Web of Science ®Google Scholar
• Planella T, Cortes M, Martinez-Bru C, Gonzalez-Sastre F, Ordonez-Llanos J. Calculation of LDL-cholesterol by using apolipoprotein B for classification of nonchylomicronemic dyslipidemia. Clin Chem 1999; 43: 808–15
   Google Scholar
• Wagner AM, Zapico E, Bonet R, Perez A, Ordonez-Llanos J. The effect of VLDL particles on the accuracy of a direct LDL-cholesterol method in type 2 diabetic patients. Clin Biochem 2003; 36: 177–83
   Google Scholar
• Ran Jun K, Park HI, Chun S, Park H, Min WK. Effects of total cholesterol and triglyceride on the percentage difference between the low-density lipoprotein cholesterol concentration measured directly and calculated using the Friedewald formula. Clin Chem Lab Med 2008; 46: 371–5
   Google Scholar
• Tighe DA, Ockene IS, Reed G, Nicolosi R. Calculated low density lipoprotein cholesterol levels frequently underestimate directly measured low density lipoprotein cholesterol determinations in patients with plasma triglyceride levels ≤ 4.52 mmol/l: an analysis comparing the LipiDirect magnetic LDL assay with the Friedewald calculation. Clin Chim Acta 2006; 365: 236–42
   Web of Science ®Google Scholar
• McFarlane C, Young IS, Hare L, Mahon G, McEneny J. A rapid methodology for the isolation of intermediate-density lipoprotein: characterization of lipid composition and apoprotein content. Clin Chim Acta 2005; 353: 117–25
   Google Scholar
• Libby P, Nathan D, Abraham K, Brunzell JD, Fradkin JE, Haffner SM, et al. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group of Cardiovascular Complications of type 1 diabetes mellitus. Circulation 2005; 111: 3489–93
   PubMed Web of Science ®Google Scholar
• Pambianco G, Costacou T, Orchard T. The prediction of major outcomes of type 1 diabetes: a 12 year prospective evaluation of three separate definitions of the metabolic syndrome, and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care 2007; 30: 1248–54
   Google Scholar
• Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hooqwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421–6
   PubMed Web of Science ®Google Scholar
• Shoji T, Nishizawa Y, Kawagishi T, Tanaka M, Kawasaki K, Tabata T, et al. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. Atherosclerosis 1997; 131: 229–36
   PubMed Web of Science ®Google Scholar
• Shoji T, Nishizawa Y, Kawagishi T, Kawasaki K, Taniwaki H, Tabata T, et al. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 1998; 9: 1277–84
   PubMed Web of Science ®Google Scholar
• Mäkinen VP, Soininen P, Forsblom C, Parkkonen M, Ingman P, Kaski K, et al. 1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death. Mol Syst Biol 2008; 4: 167
   PubMedGoogle Scholar
• Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the Thirty-Person/Ten-Country Panel. J Intern Med 2006; 259: 247–58
   PubMed Web of Science ®Google Scholar
• Pradhan A. Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders. Nutr Rev 2007; 65: 152–6
   PubMed Web of Science ®Google Scholar